...
首页> 外文期刊>European Journal of Haematology >Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.
【24h】

Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.

机译:儿童近四倍体急性淋巴细胞性白血病:EGIL研究36例。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: Patients with near-tetraploid (karyotype: 81 - 103 chromosomes) acute lymphoblastic leukemia (NT-ALL) constitute about 1% of childhood ALL and data reported on them are limited and controversial. The aim of the study was to enlarge the knowledge on these rarely occurring ALL. METHODS: The members of the European Group for Immunophenotyping of Leukemias (EGIL) searched retrospectively their databases for NT-ALL patients. RESULTS: We collected data of 36 European children from seven European countries with NT-ALL diagnosed since 1992. All patients reached complete remission (CR) after induction chemotherapy. Their blasts were negative for peroxidase and BCR-ABL1. Ten children were diagnosed as T-cell ALL (T-ALL) EGIL categories (T-I n=2, T-II n=2, T-III n=3, T-IV n=3) and four displayed various structural chromosomal abnormalities. Eight of 10 T-ALL remained in 1st CR; one died in CR from sepsis and one is alive in 2nd CR. Median survival was 88 (7-213) months. B-cell precursor (BCP) ALL was diagnosed in 26 children. Thirteen were positive for ETV6-RUNX1 and are alive in 1st CR for 32-147 months. Ten children were ETV6-RUNX1 negative and remained in 1st CR for 16-163 months. One girl with hypodiploid and NT metaphases and ETV6-RUNX1-negative BCP-ALL and one of two boys with NT-BCP-ALL not examined for ETV6-RUNX1 died of infection after stem cell transplantation in 2nd/3rd CR. Secondary myelodysplastic syndrome developed in two patients with NT-BCP-ALL. CONCLUSIONS: Our data demonstrate immunophenotypic, cytogenetic, and molecular heterogeneity of NT-ALL and favorable prognosis of most NT-ALL across different immunophenotypic and/or genetic ALL subtypes.
机译:目的:近四倍体(染色体核型:81-103条染色体)急性淋巴细胞白血病(NT-ALL)患者约占儿童ALL的1%,报道的数据有限且存在争议。该研究的目的是扩大对这些罕见的ALL的认识。方法:欧洲白血病免疫表型研究小组(EGIL)的成员回顾性地搜索了他们的NT-ALL患者数据库。结果:我们收集了自1992年以来被诊断为NT-ALL的来自七个欧洲国家的36名欧洲儿童的数据。所有患者在诱导化疗后均达到完全缓解(CR)。他们的原始细胞为过氧化物酶和BCR-ABL1阴性。十个儿童被诊断为T细胞ALL(T-ALL)EGIL类别(TI n = 2,T-II n = 2,T-III n = 3,T-IV n = 3),其中四个表现出各种结构性染色体异常。 10个T-ALL中有8个保留在第一个CR中;一名死于败血症的CR中,另一名死于第二CR。中位生存期为88(7-213)个月。在26名儿童中诊断出B细胞前体(BCP)ALL。 ETV6-RUNX1阳性13例,在第1次CR中存活32-147个月。十名儿童ETV6-RUNX1阴性,并在第一CR中停留16-163个月。一个二倍体和NT中期和ETV6-RUNX1阴性的BCP-ALL的女孩和两个未检查ETV6-RUNX1的NT-BCP-ALL的男孩之一在第二/第三次CR干细胞移植后死于感染。两名NT-BCP-ALL患者发生继发性骨髓增生异常综合征。结论:我们的数据证明了NT-ALL的免疫表型,细胞遗传学和分子异质性以及大多数NT-ALL在不同免疫表型和/或遗传ALL亚型中的良好预后。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号